METTL7A抗体—艾普蒂

+ +

•  

   

     Gel: 12%SDS-PAGE, Lysate: 40 μg, Lane 1-2: 231 cell, Human urinary bladder tissue, Primary antibody: P09198(METTL7A Antibody) at dilution 1/400, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 1 minute    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P09198(METTL7A Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

The METTL7A antibody is a tool used to study the methyltransferase-like 7A protein, a member of the methyltransferase superfamily implicated in cellular methylation processes. METTL7A is characterized by a conserved S-adenosylmethionine (SAM)-binding domain, though its specific enzymatic substrates remain under investigation. It is broadly expressed in human tissues, including the liver, kidney, and testes, and localizes to the endoplasmic reticulum. Research links METTL7A to lipid metabolism, cancer progression, and drug resistance, with upregulated expression observed in certain tumors, such as glioblastoma and hepatocellular carcinoma. Its role in lipid droplet regulation and oxidative stress response suggests potential involvement in metabolic disorders and neurodegenerative diseases.

METTL7A antibodies are typically developed in hosts like rabbits or mice, targeting specific epitopes (e.g., N-terminal regions). They are validated for applications such as Western blotting, immunohistochemistry, and immunofluorescence. Recent studies highlight METTL7A's interaction with proteins involved in lipid biosynthesis and its methylation-dependent regulatory effects on cellular pathways. However, functional ambiguities persist, necessitating further research to clarify its mechanistic contributions to disease. The antibody serves as a critical reagent for exploring METTL7A's biological significance and therapeutic potential.